VNDA Quote, Financials, Valuation and Earnings

iBio has a net margin of -11.17% compared to Vanda Pharmaceuticals's net margin of -4444.57%. Vanda Pharmaceuticals's return on equity of -3.02% beat iBio's return on equity of -148.3%.

Vanda Pharmaceuticals has a consensus price target of $10.43, signalling upside risk potential of 122.81%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 52.54%. Given that Vanda Pharmaceuticals has higher upside potential than iBio, analysts believe Vanda Pharmaceuticals is more attractive than iBio.

Vanda Pharmaceuticals has a beta of 0.757, which suggesting that the stock is 24.283% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $47.7M, which are larger than iBio quarterly revenues of $175K. Vanda Pharmaceuticals's net income of -$5.3M is lower than iBio's net income of -$4M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.42x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -11.17% compared to Vanda Pharmaceuticals's net margin of -49.65%. Vanda Pharmaceuticals's return on equity of -3.02% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Vanda Pharmaceuticals has a consensus price target of $10.43, signalling upside risk potential of 122.81%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that NovaBay Pharmaceuticals has higher upside potential than Vanda Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Vanda Pharmaceuticals.

Vanda Pharmaceuticals has a beta of 0.757, which suggesting that the stock is 24.283% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $47.7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Vanda Pharmaceuticals's net income of -$5.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.42x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -11.17% compared to Vanda Pharmaceuticals's net margin of -2357.27%. Vanda Pharmaceuticals's return on equity of -3.02% beat Palatin Technologies's return on equity of --.

Vanda Pharmaceuticals has a consensus price target of $10.43, signalling upside risk potential of 122.81%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1652.58%. Given that Palatin Technologies has higher upside potential than Vanda Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Vanda Pharmaceuticals.

Vanda Pharmaceuticals has a beta of 0.757, which suggesting that the stock is 24.283% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $47.7M, which are larger than Palatin Technologies quarterly revenues of $350K. Vanda Pharmaceuticals's net income of -$5.3M is higher than Palatin Technologies's net income of -$7.8M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.42x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -11.17% compared to Vanda Pharmaceuticals's net margin of -899.19%. Vanda Pharmaceuticals's return on equity of -3.02% beat Zevra Therapeutics's return on equity of -159.89%.

Vanda Pharmaceuticals has a consensus price target of $10.43, signalling upside risk potential of 122.81%. On the other hand Zevra Therapeutics has an analysts' consensus of -- which suggests that it could grow by 133.1%. Given that Zevra Therapeutics has higher upside potential than Vanda Pharmaceuticals, analysts believe Zevra Therapeutics is more attractive than Vanda Pharmaceuticals.

Vanda Pharmaceuticals has a beta of 0.757, which suggesting that the stock is 24.283% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.972, suggesting its more volatile than the S&P 500 by 97.163%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $47.7M, which are larger than Zevra Therapeutics quarterly revenues of $3.7M. Vanda Pharmaceuticals's net income of -$5.3M is higher than Zevra Therapeutics's net income of -$33.2M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.42x versus 14.91x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.